Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Athenex's NDA for Breast Cancer Drug Gets Priority Review

by Zacks Equity Research

The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021. Stock up.

Zacks Equity Research

Medtronic (MDT) Plans Up to $475M of Annual Cost Savings

by Zacks Equity Research

Medtronic (MDT) expects its new operating model to help it become more focused in terms of speeding up research and developments.

Zacks Equity Research

Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg

by Zacks Equity Research

Bristol Myers' (BMY) Onureg becomes the first and only FDA-approved continued AML therapy for patients in remission.

Zacks Equity Research

ResMed (RMD) Launches First CPAP Nasal Mask With Memory Foam

by Zacks Equity Research

ResMed (RMD) adds another product to its line of easy-to-use, convenient and comfortable masks.

Zacks Equity Research

Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up

by Zacks Equity Research

Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.

Zacks Equity Research

Phirbo's Product Mix Aids, Global Animal Health Business Ails

by Zacks Equity Research

Phirbo (PAHC) catered industries face issues like lack of processing availability and sudden drop in demand.

Zacks Equity Research

Medtronic's Pediatric Diabetes Device Gets Regulatory Nod

by Zacks Equity Research

MiniMed 770G is Medtronic's (MDT) MiniMed 670G System's upgraded version.

Zacks Equity Research

OMRI Clears NEOGEN's AquaPrime Peraside 15 as USDA Compliant

by Zacks Equity Research

NEOGEN (NEOG) completes organic certified water treatment program with the latest certification.

Zacks Equity Research

Syneos Health-Idorsia Collaborate to Launch Daridorexant in US

by Zacks Equity Research

Syneos Health (SYNH) inks deal with Idorsia to commercialize the treatment for insomnia in the United States.

Zacks Equity Research

Medtronic's (MDT) Cryoablation Suited for Patients With PAF

by Zacks Equity Research

Medtronic's (MDT) cryoablation therapy's superiority for the treatment of PAF over currently available AAD treatment gets reflected in trial results.